Corbus Pharmaceuticals Holdings Inc (CRBP)
followers
·
Follow
Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Yuval Cohen
Employees:
40
500 RIVER RIDGE DRIVE, NORWOOD, MA, 02062
617-963-0103
Date | Ratio |
---|---|
2023-02-14 | 1:30 |
Corbus Pharmaceuticals Holdings, Inc. focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus. CRB-601, an anti-integrin monoclonal antibody (mAb) that inhibits the activation of transforming growth factor ß (TGFß)
All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
---|